Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Arranz

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Case Reports in Hematology|January 17, 2019
A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic TransplantationPaola Villafuerte-Gutiérrez, Montserrat López Rubio, Pilar Herrera, et al.
Journal of Clinical Apheresis|March 1, 2019
Comparison and cost analysis of three protocols for mobilization and apheresis of haematopoietic progenitor cellsFrancisco López-Castaño, Pablo Manresa, Vanesa Díaz, et al.
British Journal of Haematology|May 25, 2002
Deletion of sequences flanking the t(9;22) breakpoint: a secondary genetic event associated with loss of cytogenetic response to interferon in a Philadelphia-positive chronic myeloid leukaemia patientEva Arranz, Juan José Gil-Fernández, Soraya Ramiro, et al.
Oncology Research|March 20, 2025
T-cell prolymphocytic leukemia, a case report and review of the literatureLuis Manuel GONZáLEZ-RODRíGUEZ, Luis Miguel JUáREZ-Salcedo, Javier Loscertales, et al.
Haematologica|July 15, 2003
Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemiaJuan Luis Steegmann, Gemma Moreno, Concepción Aláez, et al.
Plos One|March 3, 2012
Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinaseÁlvaro Cuesta-Domínguez, Mara Ortega, Cristina Ormazábal, et al.
Haematologica|September 13, 2005
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromesFrancesc Solé, Elisa Luño, Carmen Sanzo, et al.
Genes, Chromosomes & Cancer|March 6, 2003
De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19Juan C Cigudosa, Maria D Odero, M José Calasanz, et al.
Case Reports in Oncology|October 21, 2020
Jumping Translocation in a Patient with Acute Leukemia and Fatal EvolutionIrene Sánchez Prieto, Montserrat López Rubio, Eva Arranz, et al.
Haematologica|June 12, 2013
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO groupReyes Arranz, Ana García-Noblejas, Carlos Grande, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Case Reports in Hematology|January 17, 2019
A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic TransplantationPaola Villafuerte-Gutiérrez, Montserrat López Rubio, Pilar Herrera, et al.
Journal of Clinical Apheresis|March 1, 2019
Comparison and cost analysis of three protocols for mobilization and apheresis of haematopoietic progenitor cellsFrancisco López-Castaño, Pablo Manresa, Vanesa Díaz, et al.
British Journal of Haematology|May 25, 2002
Deletion of sequences flanking the t(9;22) breakpoint: a secondary genetic event associated with loss of cytogenetic response to interferon in a Philadelphia-positive chronic myeloid leukaemia patientEva Arranz, Juan José Gil-Fernández, Soraya Ramiro, et al.
Oncology Research|March 20, 2025
T-cell prolymphocytic leukemia, a case report and review of the literatureLuis Manuel GONZáLEZ-RODRíGUEZ, Luis Miguel JUáREZ-Salcedo, Javier Loscertales, et al.
Haematologica|July 15, 2003
Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemiaJuan Luis Steegmann, Gemma Moreno, Concepción Aláez, et al.
Plos One|March 3, 2012
Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinaseÁlvaro Cuesta-Domínguez, Mara Ortega, Cristina Ormazábal, et al.
Haematologica|September 13, 2005
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromesFrancesc Solé, Elisa Luño, Carmen Sanzo, et al.
Genes, Chromosomes & Cancer|March 6, 2003
De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19Juan C Cigudosa, Maria D Odero, M José Calasanz, et al.
Case Reports in Oncology|October 21, 2020
Jumping Translocation in a Patient with Acute Leukemia and Fatal EvolutionIrene Sánchez Prieto, Montserrat López Rubio, Eva Arranz, et al.
Haematologica|June 12, 2013
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO groupReyes Arranz, Ana García-Noblejas, Carlos Grande, et al.
Pageof 2